Enzyme Prodrug Therapy with Photo-Cross-Linkable Anti-EGFR Affibodies Conjugated to Upconverting Nanoparticles
Open Access
- 21 September 2022
- journal article
- research article
- Published by American Chemical Society (ACS) in ACS Nano
- Vol. 16 (10) , 15873-15883
Abstract
In this work, we demonstrate that a photo-cross-linkable conjugate of upconverting nanoparticles and cytosine deaminase can catalyze prodrug conversion specifically at tumor sites in vivo. Non-covalent association of proteins and peptides with cellular surfaces leads to receptor-mediated endocytosis and catabolic degradation. Recently, we showed that covalent attachment of proteins such as affibodies to cell receptors yields extended expression on cell surfaces with preservation of protein function. To adapt this technology for in vivo applications, conjugates were prepared from upconverting nanoparticles and fusion proteins of affibody and cytosine deaminase enzyme (UC-ACD). The affibody allows covalent photo-cross-linking to epidermal growth factor receptors (EGFRs) overexpressed on Caco-2 human colorectal cancer cells under near-infrared (NIR) light. Once bound, the cytosine deaminase portion of the fusion protein converts the prodrug 5-fluorocytosine (5-FC) to the anticancer drug 5-fluorouracil (5-FU). NIR covalent photoconjugation of UC-ACD to Caco-2 cells showed 4-fold higher retention than observed with cells that were not irradiated in vitro. Next, athymic mice expressing Caco-2 tumors showed 5-fold greater UC-ACD accumulation in the tumors than either conjugates without the CD enzyme or UC-ACDs in the absence of NIR excitation. With oral administration of 5-FC prodrug, tumors with photoconjugated UC-ACD yielded 2-fold slower growth than control groups, and median mouse survival increased from 28 days to 35 days. These experiments demonstrate that enzyme-decorated nanoparticles can remain viable after a single covalent photoconjugation in vivo, which can in turn localize prodrug conversion to tumor sites for multiple weeks.Keywords
Funding Information
- U.S. Department of Health and Human Services (R21AR078506)
- U.S. Department of Health and Human Services (R21GM135668)
This publication has 64 references indexed in Scilit:
- Tumor Targeting Using Affibody Molecules: Interplay of Affinity, Target Expression Level, and Binding Site CompositionJournal of Nuclear Medicine, 2012
- Monoclonal antibodies: versatile platforms for cancer immunotherapyNature Reviews Immunology, 2010
- Biodistribution Mechanisms of Therapeutic Monoclonal Antibodies in Health and DiseaseThe AAPS Journal, 2009
- Tag–probe labeling methods for live-cell imaging of membrane proteinsBiochimica et Biophysica Acta (BBA) - Biomembranes, 2009
- The recycling and transcytotic pathways for IgG transport by FcRn are distinct and display an inherent polarityJournal of Cell Biology, 2009
- Affinity and Avidity in Antibody-Based Tumor TargetingCancer Biotherapy and Radiopharmaceuticals, 2009
- Antitumor Therapy Mediated by 5-Fluorocytosine and a Recombinant Fusion Protein Containing TSG-6 Hyaluronan Binding Domain and Yeast Cytosine DeaminaseMolecular Pharmaceutics, 2009
- Matuzumab Binding to EGFR Prevents the Conformational Rearrangement Required for DimerizationCancer Cell, 2008
- Tumor Growth Inhibition with Cetuximab and Chemotherapy in Non–Small Cell Lung Cancer Xenografts Expressing Wild-type and Mutated Epidermal Growth Factor ReceptorClinical Cancer Research, 2007
- Random mutagenesis and selection of Escherichia coli cytosine deaminase for cancer gene therapyProtein Engineering, Design and Selection, 2004